



PacBio and Verily Health Announce Multi-Year Strategic Collaboration to Scale Long-Read Genomics for Biomedical AI

October 19, 2026 at 9:05 AM EDT

Verily Pre will connect PacBio HiFi Sequencing with governed cloud analysis, multimodal health data and AI-ready research workflows

MENLO PARK, Calif. and DALLAS, Oct. 19, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, and Verily Health Inc., a healthcare data intelligence company, announced today a multi-year strategic collaboration to integrate PacBio HiFi sequencing with Verily Health's governed data and AI platform. The collaboration will link PacBio sequencing workflows to Verily Pre, combining long-read genomic data with real-world clinical data at population scale. The resulting AI-ready clinico-genomic datasets will support biomedical discovery efforts and AI model training and deployment.

The collaboration addresses a growing bottleneck in biomedical AI: increasingly powerful models require biological data with greater depth, context and scale. Long-read sequencing can reveal complex genetic variants, structural changes, methylation information, and full-length RNA transcripts that are difficult to capture with short-read approaches, offering richer insights into disease biology. Yet, processing these large, complex datasets and integrating them with clinical data for model training remains fragmented, unscalable and largely bespoke. PacBio and Verily Health intend to connect those steps, making rich genomic data more accessible and usable to power the next generation of biomedical AI applications. Verily Pre already supports population-scale biomedical research, while Workbench serves more than 20,000 researchers and has supported more than 700 publications. And because PacBio HiFi whole-genome sequencing workflows already run end-to-end within the Verily Pre environment, it provides an existing and robust technical foundation for the multi-year collaboration.

"This collaboration reflects a shared focus on making high-quality genomic data more accessible and useful across research and development, while creating a foundation for continued innovation in health," said Stephen Gillett, Chairman and CEO of Verily Health. "Working with PacBio, we hope to deliver a meaningful impact to researchers and innovators working to find new answers for neurology, oncology, rare disease, and other areas of critical unmet need."

"PacBio HiFi sequencing offers our customers the most complete and highest quality data available, which is ideal for training AI models where the input determines the success of the output" said Mark Van Oene, President and CEO of PacBio. "Through this collaboration with Verily Health, we are building a path to turn richer biological data into AI-ready data at scale to ultimately help researchers get more from both their sequencing and their models."

Verily Pre provides the foundation to build, deploy and scale intelligent applications across healthcare and life sciences. Under the collaboration, Verily Health will configure Pre Workbench to connect PacBio sequencing workflows, acting as the secure governed research environment for the aggregation, analysis, and curation of HiFi genomic datasets. The companies also plan to use the Verily Pre trusted agentic environment (TAE) to run model training and inference, enabling researchers to explore deeper, longitudinal genomic datasets and support their workflows. Over the course of the multi-year collaboration, PacBio and Verily Health plan to expand the integration to support increasingly large and complex long-read programs across research organizations, biopharma and population genomics. The companies envision a common infrastructure that can scale with increasingly large and complex long-read programs, supporting multimodal research and AI development across biopharma, clinical institutions, population genomics and other areas of precision health.

About PacBio

PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which include our HiFi long-read sequencing, address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

About Verily Health Inc.

At the intersection of technology, data science, and healthcare, Verily Health transforms complex health data into trusted intelligence, enabling health solutions that are more personal, predictive, and precise.

Verily's flagship Governed Health Intelligence platform, Verily Pre, enables healthcare organizations to responsibly govern, model, and securely activate their protected health data at scale, deploying intelligence with the scientific rigor, oversight, and auditability needed for healthcare.

For more information about Verily Health, please visit verily.com

Disclaimer:

The Verily Pre platform is not a medical device and has not been evaluated by the FDA. Customers developing Software as a Medical Device (SaMD) are solely responsible for regulatory compliance.

Forward looking statements

This press release may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the availability, uses, accuracy, advantages, quality or performance of, or benefits of using, or expected benefits of using, PacBio products or technologies, including in connection with the collaboration between PacBio and Verily Health; plans to integrate PacBio HiFi sequencing with Verily Health's governed data and AI platform to create AI-ready clinico-genomic datasets; making genomic data more accessible and usable to power future biomedical AI application and create a foundation for continued innovation in health; impact in finding new answers for

neurology, oncology, rare disease, and other areas of critical unmet need; building a path to turn richer biological data into AI-ready data; Verily Health configuring Pre Workbench as secure governed research environment; the use of TAEs to run model training and inference; developing a common infrastructure capable of supporting increasingly large and complex long-read programs; and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, challenges inherent in using , and collaborating with third parties to develop, new technologies; potential product performance, interoperability and quality issues; potential regulatory issues relating to the development and use AI technologies; rapidly changing technologies and extensive competition in, and potential FDA regulatory issues relating to, genomic sequencing; unanticipated increases in costs or expenses; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights, among others. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.

Media Contacts

PacBio

Investors:

ir@pacb.com

Media:

pr@pacb.com

Verily Health

Laurie Ferguson

verily-press@verily.com